GlassScriptPhysician profile
Ashok M Patel
NPI 1124091798
$7,016.33
in general payments reported to CMS, 2019-2025
35 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.64 · 2020: $160 · 2021: $1,289 · 2022: $875 · 2023: $1,039 · 2024: $1,610 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,628 · Education: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,628.21 |
| Education | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,327.95 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,040.47 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $598.60 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $537.05 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $504.24 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $454.79 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $303.08 | 2023-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $276.44 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $215.06 | 2019-2025 | Spravato, Invega, Invega Sustenna |
| Alkermes, INC. | $188.37 | 2020-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $188.33 | 2020-2022 | |
| Noven Therapeutics, LLC | $172.67 | 2024-2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $151.96 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $147.09 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $116.91 | 2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $110.64 | 2021-2025 | Loreev Xr, Gralise |
| Tris Pharma INC | $108.67 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Neos Therapeutics, LP | $103.24 | 2022-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $91.50 | 2021-2023 | Jornay Pm |
| Indivior INC. | $71.47 | 2024 | Sublocade |
| Merck Sharp & Dohme LLC | $43.95 | 2022 | |
| Vanda Pharmaceuticals INC. | $43.59 | 2024 | Fanapt, Hetlioz |
| Livanova USA, INC. | $42.26 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $40.17 | 2021-2022 | |
| Corium, LLC | $37.80 | 2022-2023 | Azstarys |
| Eisai INC. | $34.86 | 2021 | |
| Pfizer INC. | $19.37 | 2025 | |
| Alfasigma USA, INC. | $17.94 | 2020 | |
| Adlon Therapeutics L.P. | $16.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.86 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.